PGNY · NASDAQ · Medical - Healthcare Plans

Progyny (PGNY)

Manages employer fertility benefits with bundled care, navigation, provider networks, and pharmacy coordination.

$26.17
vs last close−0.07 (−0.27%)
Loading prices…

Progyny, Inc.PGNY
Health Care

Manages employer-sponsored fertility, family-building, and women's health benefits through bundled treatments, member navigation, provider networks, and an integrated pharmacy benefit supported by specialty-pharmacy partners. Revenue is driven mainly by members' use of fertility care and medications, making covered lives and utilization central to results.

Manages fertility, family-building, and women's health benefits, primarily for U.S. employers. Smart Cycle bundles fertility treatments; Progyny Rx coordinates medications through specialty pharmacies. Care Advocates, digital tools, and a managed provider network connect members with care.

Adjacent programs cover pregnancy and postpartum, menopause and midlife, leave navigation, parent and child wellbeing, reimbursements for adoption and surrogacy, and international needs through Progyny Global. Progyny Select adds a fully insured supplemental plan for smaller U.S. employers.

Most revenue follows members' use of fertility treatment and medications; a smaller population fee supports navigation and digital tools. Results depend on client renewals, covered lives, utilization mix, provider and pharmacy networks, and reproductive-health, insurance, privacy, and pharmacy regulation.

Company facts

CEOPeter Anevski
ListedOct 24, 2019
ExchangeNASDAQ
HeadquartersNew York, NY
CountryUnited States
Employees856
CIK0001551306
ISINUS74340E1038

Market cap$2.06B
EPS (ttm)$0.9200
P/E (ttm)28.52
ROE16.0%
P/B4.53
P/S1.57
Dividend yieldDiv yield
Beta0.34vs XLV −0.03

Price target$35.50+35.3%Average of 20 analysts
ConsensusBuy14 of 20 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 8, 2026JefferiesTarget
Target: $30
Target: $33
Aug 20, 2026Wells FargoInitiate
Rating: Target:
Rating: OverweightTarget: $37
Aug 13, 2026Truist FinancialTarget
Target: $28
Target: $36
Aug 12, 2026BarclaysReiterate
Rating: Target: $34
Rating: Equal WeightTarget: $30
Aug 7, 2026Canaccord GenuityTarget
Target: $36
Target: $35

Next report
Nov 5, 26
in 43 days
EPS estimate
$0.51
Revenue estimate
$340.6M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.12$0.18$0.20$0.16$0.15$0.30$0.36Pending
Estimate$0.11$0.19$0.17$0.39$0.15$0.26$0.33$0.51
Surprise+9.1%−5.5%+17.6%−59.0%+2.0%+17.2%+7.5%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$298.4M$324.0M$332.9M$313.3M$318.4M$328.5M$350.5MPending
Estimate$277.8M$307.9M$320.1M$299.3M$307.4M$326.5M$349.0M$340.6M
Surprise+7.4%+5.3%+4.0%+4.7%+3.6%+0.6%+0.4%
Estimate$0.51
ReportedDue Nov 5, 2026
Estimate$340.6M
ReportedDue Nov 5, 2026
View details

Debt to equity6.00%
Current ratio213.70%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$286.6M$298.4M$324.0M$332.9M$313.3M$318.4M$328.5M$350.5M
Net income$10.4M$10.5M$15.1M$17.1M$13.9M$12.5M$24.2M$28.1M
Net margin3.6%3.5%4.6%5.1%4.4%3.9%7.4%8.0%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$12.5M$15.8M$24.2M$24.4M$21.5M$15.2M$35.4M$40.0M
YoY growth−31.5%+14.4%+30.5%+17.7%+72.8%−3.6%+46.4%+64.2%

Balance sheet, Jun 30, 2026Cash & short-term investments $236.9M · Total debt $27.0M · Total assets $715.8M · Shareholders' equity $453.3M

Revenue
$350.5M
Operating income
$40.0M
Net income
$28.1M
View details

No dividends on record.

Institutions≈ 100.80%78.96M shares
317 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail
Insiders8.75%6.85M shares
15 holders · as of Sep 21, 2026
Strategic holders9.56%7.49M shares
2 holders · as of Feb 14, 2022
Adds to119.11%

78.33M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.

These groups come from separate filings that can overlap, so they add to 119.11%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
14.81%11.60Mas of Jun 30, 2026
FMR LLCInstitution
8.94%7.00Mas of Jun 30, 2026
Thrivent Financial For LutheransInsider
6.83%5.35Mfiled Apr 29, 2025
Vanguard Portfolio Management LLCInstitution
6.41%5.02Mas of Jun 30, 2026
Alger Group Holdings, LLCStrategic
5.82%4.56Mfiled Feb 14, 2022

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Sep 10, 2026Kevin K. Gordondirector−23,000$27.53
Jul 14, 2026Melissa B. Cummingsofficer: Chief Operating Officer−2,244$31.60
Jun 4, 2026Allison Swartzofficer: EVP, GC−599$25.08
Jun 3, 2026Allison Swartzofficer: EVP, GC−1,199$25.02
Jun 4, 2026Mark S. Livingstonofficer: CHIEF FINANCIAL OFFICER−2,517$25.50
View details

  • UnitedHealth Group

    Largest managed-care insurer embedding fertility benefits in UHC health plans

  • CVS Health

    Insurer-PBM pairing Aetna fertility plan management with CVS Specialty pharmacy

  • Cigna

    Major health insurer and top-3 PBM with competing fertility and Rx programs

  • Teladoc Health

    Dominant U.S. virtual care platform serving 93M+ members across employer clients

  • Bright Horizons Family Solutions

    Largest U.S. employer-sponsored childcare and back-up care benefits provider

Compare

CompanyPriceChange
Progyny$26.17−0.27%$2.06B28.516.51.6+5.3%
UnitedHealth Group$368.47−1.20%$338.69B24.017.30.8+0.4%
CVS Health$85.99−1.27%$111.13B23.010.60.3+7.3%
Cigna$272.36−0.50%$72.33B11.38.60.3+6.6%
Teladoc Health$6.22−2.05%$1.15B0.5−4.0%
Bright Horizons Family Solutions$64.71−0.38%$3.42B20.612.01.1+6.5%
Median21.811.30.5+6.5%